Evidence map›Paper›PMID 25349153›Full record

ArticleLeukemia2015

Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.

C Pepper, A G S Buggins, C H Jones, E J Walsby, F Forconi, G Pratt, S Devereux, F K Stevenson, C Fegan

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Presenting features and treatment outcomes of chronic lymphocytic leukaemia in a resource poor Southern Nigeria.Malawi medical journal : the journal of Medical Association of Malawi · 2019
    Article
  3. Article
  4. Chronic lymphocytic leukaemia.Nature reviews. Disease primers · 2017
    Review
  5. Article
  6. Article
  7. Article
  8. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

C PepperCardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
A G S BugginsDepartment of Haematology, King's College London, London, UK.
C H JonesCardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
E J WalsbyCardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.
F ForconiCancer Sciences Unit, CRUK Clinical Centre, University of Southampton, Southampton, UK.
G PrattCRUK Institute for Cancer Studies, University of Birmingham, Birmingham, UK.
S DevereuxDepartment of Haematology, King's College London, London, UK.
F K StevensonCancer Sciences Unit, CRUK Clinical Centre, University of Southampton, Southampton, UK.
C FeganCardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Gene Expression Regulation, NeoplasticAdenineAgammaglobulinaemia Tyrosine KinaseAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzylaminesChemokine CXCL12Class I Phosphatidylinositol 3-KinasesCyclamsGenetic HeterogeneityHeterocyclic CompoundsHumansImmunoglobulin Heavy ChainsIntegrin alpha4Leukemia, Lymphocytic, Chronic, B-CellMutationAdenineAgammaglobulinaemia Tyrosine KinaseAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBenzylaminesBTK protein, humanChemokine CXCL12Class I Phosphatidylinositol 3-KinasesCXCL12 protein, humanCXCR4 protein, humanCyclamsHeterocyclic CompoundsibrutinibidelalisibImmunoglobulin Heavy ChainsIntegrin alpha4NatalizumabPIK3CD protein, humanPiperidinesplerixaforProtein-Tyrosine KinasesPurinesPyrazolesPyrimidinesQuinazolinonesReceptors, CXCR4

Identifiers

PMID25349153
PMCPMC4360209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.